Hi mate
It's subscriber only and a video so i don't think a link will work
Key points
- Aussie market 3-6 months
- Europe q1 2018 (offices to be set up in U.K. And Germany with distributors in other countries)
- FDA approval q2 2018 at which time they will have the cash flow to drive business
- re-emphasized the dsa agreement. Looks like they definitely will partner with Hammond care in uk as a starter and take a similar approach
- pain will be recognized as a vital sign once they are finished and the market will be as big as diabetes market ($10b) if Phil has his way
He's using the cochlear and Roche playbook. I Should've bought more!
Hi mate It's subscriber only and a video so i don't think a link...
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
